论文部分内容阅读
目的观察胃癌患者外周血中多药耐药基因(MDR1)的表达水平,并探讨其对提示肿瘤化学治疗耐药性的临床意义。方法选择42例胃癌初治患者,实施荧光定量逆转录PCR法检测其外周血MDR1 mRNA表达情况,并以肿瘤组织中的MDR mRNA表达水平为参照,分析外周血MDR1 mRNA阳性率对肿瘤化学治疗耐药性的诊断效能。结果 42例胃癌患者中,外周血MDR1基因阳性表达率为45.2%,肿瘤组织MDR1 mRNA阳性率为67.7%。胃癌患者的外周血MDR1 mRNA阳性者中,高龄、高分化、肿瘤直径≥3cm者所占比例与肿瘤组织MDR1 mRNA阳性比较差异无统计学意义(P>0.05)。外周血MDR1 mRNA诊断肿瘤耐药的敏感度为67.9%,特异度100%。结论外周血中MDR1基因表达与肿瘤组织中的表达具有一致性,前者可作为后者的补充。
Objective To observe the expression of multidrug resistance gene (MDR1) in peripheral blood of patients with gastric cancer and to explore its clinical significance to suggest the chemoresistance of tumor chemotherapy. Methods Forty-two patients with newly diagnosed gastric cancer were enrolled in this study. The expression of MDR1 mRNA in peripheral blood was detected by fluorescence quantitative reverse transcription polymerase chain reaction (RT-PCR). The MDR mRNA expression in the tumor tissue was used as a reference to analyze the positive rate of MDR1 mRNA in peripheral blood Medicinal diagnostic efficacy. Results The positive rate of MDR1 gene in peripheral blood was 45.2% in 42 gastric cancer patients, and the positive rate of MDR1 mRNA in tumor tissues was 67.7%. There was no significant difference in the proportion of MDR1 mRNA positive in gastric cancer patients with MDR1 mRNA positive, advanced age, well-differentiated, and tumor diameter ≥3 cm (P> 0.05). The sensitivity of peripheral blood MDR1 mRNA in diagnosing tumor drug resistance was 67.9% and the specificity was 100%. Conclusion The expression of MDR1 gene in peripheral blood is consistent with the expression in tumor tissue. The former can be used as a supplement to the latter.